NCT00703924View on ClinicalTrials.gov

Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World

PHASE2CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

November 30, 2004

Study Completion Date

November 30, 2005

Conditions
Cutaneous Leishmaniasis
Interventions
DRUG

WR 279,396

A topical cream containing 15% paromomycin and 0.5% gentamicin. Approximately 0.0005 mL per mm2 of skin lesion

DRUG

Placebo

Topical cream vehicle. Approximately 0.0005 mL per mm2 of skin lesion

Trial Locations (2)

75015

Medical Center Institut Pasteur, Paris

Unknown

Institue Pasteur, Tunis

All Listed Sponsors
collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

lead

U.S. Army Medical Research and Development Command

FED

NCT00703924 - Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World | Biotech Hunter | Biotech Hunter